Patents Examined by Shubo Zhou
  • Patent number: 6673910
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Moracella catarrhalis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: April 4, 2000
    Date of Patent: January 6, 2004
    Assignee: Genome Therapeutics Corporation
    Inventor: Gary L. Breton
  • Patent number: 6638718
    Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: October 28, 2003
    Assignee: Essential Therapeutics, Inc.
    Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
  • Patent number: 6640191
    Abstract: Methods for generating multiple rounds of combinatorial libraries, which use Monte Carlo methods to search the multi-dimensional composition and non-composition space of variables in combinatorial chemistry; the combinatorial libraries generated and screened by such Monte Carlo methods; and an apparatus for generating and screening such libraries robotically. The process involves preparing a first set of samples, then changing the composition and non-composition variables of the samples using Monte Carlo sampling methods, and accepting proposed new samples according to a detailed balance acceptance criterion.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: October 28, 2003
    Assignee: The Regents of the University of California
    Inventors: Michael W. Deem, Marco Falcioni
  • Patent number: 6635742
    Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted semaphorin-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from fetal liver-spleen (Hyseq clone identification numbers 5688868 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted semaphorin-like polypeptides, and antibodies specific for such polypeptides.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: October 21, 2003
    Assignee: Nuvelo, Inc.
    Inventors: Bryan J. Boyle, George Yeung, Matthew C. Arterburn, Nancy K. Mize, Y. Tom Tang, Chenghua Liu, Radoje T. Drmanac
  • Patent number: 6630305
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.
    Type: Grant
    Filed: October 10, 2000
    Date of Patent: October 7, 2003
    Assignee: Corixa Corporation
    Inventors: Jiangchun Xu, Davin C. Dillon, Jennifer L. Mitcham, Susan L. Harlocker, Yuqiu Jiang, Michael D. Kalos, Gary R. Fanger, Marc W. Retter, John A. Stolk, Craig H. Day, Thomas S. Vedvick, Darrick Carter, Samuel X. Li, Aijun Wang, Yasir A. W. Skeiky, William T. Hepler, Robert A. Henderson
  • Patent number: 6630303
    Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: October 7, 2003
    Assignee: Essential Therapeutics, Inc.
    Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
  • Patent number: 6629040
    Abstract: The present invention provides methods and reagents for identifying specific masses of compounds in a complex mixture. In particular, the present invention describes an isotope distribution encoded tag (IDEnT) concept wherein the ability to distinguish an analyte encoded with a non-native isotope from those not encoded with the isotope or from those encoded with a different isotope is used for protein identification, enzyme active site identification, peptide sequencing, and the like. Reagents used in the IDEnT strategy consist of a chemical element with a unique isotope distribution not normally found in the analyte class being studied, chemically bonded to, or an integral part of a chemical reagent with a high selectivity of affinity for specific functional group in the analyte.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: September 30, 2003
    Assignees: University of Washington, Battelle Memorial Institute
    Inventors: David R. Goodlett, James E. Bruce, Beate Rist, Richard D. Smith, Ruedi Aebersold
  • Patent number: 6629038
    Abstract: A method of marking individuals of commercially distributed organism or organisms and offspring thereof is disclosed. The method is effected by genetically marking a plurality of individuals of the organism or organisms with a plurality of unique DNA sequences, each of the unique DNA sequences includes a variable region, so as to produce artificial, inherited and detectable genetic variability among the plurality of individuals of the commercially distributed organism or organisms.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: September 30, 2003
    Assignee: Yeda Research and Development Co. Ltd.
    Inventor: Jonathan Gressel
  • Patent number: 6610836
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Klebsiella pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: August 26, 2003
    Assignee: Genome Therapeutics Corporation
    Inventors: Gary L. Breton, Mark Osborne
  • Patent number: 6605709
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Proteus fragilis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: August 12, 2003
    Assignee: Genome Therapeutics Corporation
    Inventor: Gary L. Breton
  • Patent number: 6559294
    Abstract: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: May 6, 2003
    Assignee: Genset, S.A.
    Inventors: Remy Griffais, Susan K. Hoiseth, Robert John Zagursky, Benjamin J. Metcalf, Joel A. Peek, Banumathi Sankaran, Leah Diane Fletcher
  • Patent number: 6489102
    Abstract: Disclosed is a process to construct multi-component biomolecule or cellular arrays suitable for use in SPR imaging studies of large molecule, cellular/molecular, and cell/cell interactions. The success of the procedure hinges on the use of a reversible protecting group to modify reversibly &ohgr;-functionalized alkanethiols self-assembled on metal substrates.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: December 3, 2002
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Robert M. Corn, Anthony G. Frutos, Jennifer M. Brockman
  • Patent number: 6482935
    Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: November 19, 2002
    Assignee: Applera Corporation
    Inventors: Ming-Hui Wei, Shiaoping Zhu, Trevor Woodage, Valentina Di Francesco, Ellen M. Beasley
  • Patent number: 6468970
    Abstract: The in vivo circulating life and/or absorption of Neurophic Factor-3 (NT-3) is increased by generating certain substitution analogs of the native protein sequence that result in a lower isoelectric point and charge in relation to NT-3 of native sequence.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: October 22, 2002
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Patent number: 6459996
    Abstract: The present invention provides for crystalline GFS. The crystal structure of GFS has also been solved using such material. Models based upon such crystal structure are also provided. Methods of identifying inhibitors of GFS activity using such models are also disclosed.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: October 1, 2002
    Assignee: American Home Products Corporation
    Inventors: William S. Somers, Mark L. Stahl, Francis X. Sullivan
  • Patent number: 6434490
    Abstract: A computer based, iterative process for generating chemical entities with defined physical, chemical and/or bioactive properties. During each iteration of the process, (1) a directed diversity chemical library is robotically generated in accordance with robotic synthesis instructions; (2) the compounds in the directed diversity chemical library are analyzed to identify compounds with the desired properties; (3) structure-property data are used to select compounds to be synthesized in the next iteration; and (4) new robotic synthesis instructions are automatically generated to control the synthesis of the directed diversity chemical library for the next iteration.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: August 13, 2002
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Dimitris K. Agrafiotis, Roger F. Bone, Francis R. Salemme, Richard M. Soll
  • Patent number: 6426072
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compositions may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: July 30, 2002
    Assignee: Corixa Corporation
    Inventors: Tongtong Wang, Liqun Fan, Michael D. Kalos, Chaitanya S. Bangur, Nancy A. Hosken, Gary R. Fanger, Samuel X. Li, Aijun Wang, Yasir A. W. Skeiky, Robert A. Henderson, Patricia D. McNeill
  • Patent number: 6329505
    Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, are disclosed. Compositions may comprise one or more prostate-specific proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a prostate-specific protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as prostate cancer. Diagnostic methods based on detecting a prostate-specific protein, or mRNA encoding such a protein, in a sample are also provided.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: December 11, 2001
    Assignee: Corixa Corporation
    Inventors: Jiangchun Xu, Davin C. Dillon, Jennifer L. Mitcham, Susan L. Harlocker, Jiang Yuqiu, Steve G. Reed, Michael D. Kalos, Gary R. Fanger, Marc W. Retter, John A. Stolk, Craig H. Day
  • Patent number: 6271364
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Ellen Ngoi Yin Cheung, Thomas Charles Boone, Susan Irene Hershenson, John David Young